TABLE 1.
Baseline Characteristics of the 2 Treatment Groups
| Treatment A: Fish Oil (Range) |
Treatment B: Fenofibrate (Range) |
|
|---|---|---|
| No. subjects | 50 | 50 |
| Age (y) | 43.5 (26 to 61) | 43 (23 to 58) |
| Gender | 90% male | 96% male |
| Ethnicity | 58% white | 56% white |
| 16% black | 12% black | |
| 26% Hispanic | 30% Hispanic | |
| CD4 count (cells/μL) | 429.5 (114 to 1264) | 528.5 (109 to 1111) |
| HIV RNA level (copies/mL) |
<50 (<50 to 1483) | <50 (<50 to 4210) |
| Screening serum lipids | ||
| TG (mg/dL) | 668 (402 to 2980) | 667 (401 to 1922) |
| LDL-C (mg/dL) | 85 (31 to 152) | 73 (30 to 160) |
| HDL-C (mg/dL) | 31 (21 to 43) | 30 (21 to 42) |
| TC (mg/dL) | 243.5 (147 to 457) | 240.5 (158 to 447) |
| Non-HDL-C (mg/dL) | 209 (125 to 436) | 209.5 (132 to 421) |
| Medications Subjects on lopinavir/ritonavir (any ritonavir- containing regimen) |
18 (26) | 21 (32) |
| Subjects on EFV (on NVP) |
29 (4) | 20 (0)* |
| Subjects on d4T | 6 | 9 |
| Subjects on TDF | 21 | 14 |
All values for age, CD4 cell count, HIV RNA level, and serum lipids are medians and ranges.
*
P < 0.05, proportion on EFV or NVP, treatment A versus treatment B.
d4T indicates stavudine; EFV, efavirenz; NVP, nevirapine; TDF, tenofovir disoproxil fumarate.